BRIEF-J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation

Reuters

Jul 16, 2025

July 16 (Reuters) - Johnson & Johnson JNJ.N:

J&J: ANTICIPATE SECOND HALF OPERATIONAL SALES GROWTH HIGHER THAN FIRST HALF - PRESENTATION
J&J: IN INNOVATIVE MEDICINE, NEGATIVE IMPACT OF PART D RE-DESIGN, AS A PERCENT TO SALES, WILL BE CONSISTENTLY APPLIED THROUGHOUT YEAR
J&J: PRODUCTS NEGATIVELY IMPACTED BY PART D RE-DESIGN INCLUDE STELARA, INVEGA LONG ACTING INJECTABLES, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA & IMBRUVICA

Source text: [ID:]

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2551678140"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551678140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551678140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551678140","market":"nz","top_or_hot":-1,"title":"BRIEF-J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-J&amp;J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation</title></head><body><p><span>July 16 (Reuters)</span><span> - </span>Johnson &amp; Johnson <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span>:</p><ul><li><p>J&amp;J: ANTICIPATE SECOND HALF OPERATIONAL SALES GROWTH HIGHER THAN FIRST HALF - PRESENTATION</p></li><li><p>J&amp;J: IN INNOVATIVE MEDICINE, NEGATIVE IMPACT OF PART D RE-DESIGN, AS A PERCENT TO SALES, WILL BE CONSISTENTLY APPLIED THROUGHOUT YEAR</p></li><li><p>J&amp;J: PRODUCTS NEGATIVELY IMPACTED BY PART D RE-DESIGN INCLUDE STELARA, INVEGA LONG ACTING INJECTABLES, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA &amp; IMBRUVICA</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>JNJ.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-16 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-J&amp;J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation</title></head><body><p><span>July 16 (Reuters)</span><span> - </span>Johnson &amp; Johnson <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span>:</p><ul><li><p>J&amp;J: ANTICIPATE SECOND HALF OPERATIONAL SALES GROWTH HIGHER THAN FIRST HALF - PRESENTATION</p></li><li><p>J&amp;J: IN INNOVATIVE MEDICINE, NEGATIVE IMPACT OF PART D RE-DESIGN, AS A PERCENT TO SALES, WILL BE CONSISTENTLY APPLIED THROUGHOUT YEAR</p></li><li><p>J&amp;J: PRODUCTS NEGATIVELY IMPACTED BY PART D RE-DESIGN INCLUDE STELARA, INVEGA LONG ACTING INJECTABLES, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA &amp; IMBRUVICA</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>JNJ.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nFWN3TC15K:1","article_id":"2551678140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551678140","pubTimestamp":1752666208,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - PresentationJuly 16  - Johnson & Johnson JNJ.N:J&J: ANTICIPATE SECOND HALF OPERATIONAL SALES GROWTH HIGHER THAN FIRST HALF - PRESENTATIONJ&J: IN INNOVATIVE MEDICINE, NEGATIVE IMPACT OF PART D RE-DESIGN, AS A PERCENT TO SALES, WILL BE CONSISTENTLY APPLIED THROUGHOUT YEARJ&J: PRODUCTS NEGATIVELY IMPACTED BY PART D RE-DESIGN INCLUDE STELARA, INVEGA LONG ACTING INJECTABLES, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA & IMBRUVICASource text: [ID:]Further company coverage: JNJ.N ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"简介-强生预计下半年运营销售额增长高于上半年-演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"BRIEF-J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - PresentationJuly 16 (Reuters) - Johnson & Johnson JNJ.N:J&J: ANTICIPATE SECOND HALF OPERATIONAL SALES GROWTH HIGHER THAN FIRST HALF - PRESENTATIONJ&J: IN INNOVATIVE MEDICINE, NEGATIVE IMPACT OF PART D RE-DESIGN, AS A PERCENT TO SALES, WILL BE CONSISTENTLY APPLIED THROUGHOUT YEARJ&J: PRODUCTS NEGATIVELY IMPACTED BY PART D RE-DESIGN INCLUDE STELARA, INVEGA LONG ACTING INJECTABLES, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA & IMBRUVICASource text: [ID:]Further company coverage: JNJ.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}